Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) EBIT (2020 - 2025)

Historic EBIT for NeuroPace (NPCE) over the last 6 years, with Q3 2025 value amounting to -$2.6 million.

  • NeuroPace's EBIT rose 3872.26% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.2 million, marking a year-over-year increase of 2100.22%. This contributed to the annual value of -$21.7 million for FY2024, which is 2025.1% up from last year.
  • As of Q3 2025, NeuroPace's EBIT stood at -$2.6 million, which was up 3872.26% from -$6.8 million recorded in Q2 2025.
  • Over the past 5 years, NeuroPace's EBIT peaked at -$2.6 million during Q3 2025, and registered a low of -$11.0 million during Q2 2022.
  • For the 5-year period, NeuroPace's EBIT averaged around -$6.7 million, with its median value being -$6.2 million (2021).
  • As far as peak fluctuations go, NeuroPace's EBIT tumbled by 43542.02% in 2021, and later soared by 4876.76% in 2023.
  • NeuroPace's EBIT (Quarter) stood at -$9.0 million in 2021, then fell by 9.36% to -$9.9 million in 2022, then soared by 48.77% to -$5.1 million in 2023, then increased by 27.68% to -$3.7 million in 2024, then rose by 28.83% to -$2.6 million in 2025.
  • Its EBIT stands at -$2.6 million for Q3 2025, versus -$6.8 million for Q2 2025 and -$5.1 million for Q1 2025.